Comparison of the Effects of Ciprofol and Propofol on Postoperative Nausea and Vomiting in Patients Undergoing Outpatient Hysteroscopy
Huaming Zhang,Min Zhang,Lina Hao,Qianqian Li,Qijian Li,Jia Yang,Yanhu Xie
DOI: https://doi.org/10.2147/dddt.s489223
IF: 4.3188
2024-12-06
Drug Design Development and Therapy
Abstract:Huaming Zhang, &ast Min Zhang, &ast Lina Hao, Qianqian Li, Qijian Li, Jia Yang, Yanhu Xie Department of Anaesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yanhu Xie, Email Purpose: To evaluate and compare the effects of ciprofol and propofol on postoperative nausea and vomiting (PONV) in patients undergoing outpatient hysteroscopy. Design: Double-blind randomized controlled trial. Methods: This study included 1104 patients scheduled for elective outpatient hysteroscopy. Patients were randomly grouped to ciprofol Group (Group C, n = 539) and propofol Group (Group P, n = 547). Anesthesia was induced by sufentanil 0.1 ug/kg combined with ciprofol 0.3mg/kg or propofol 2.5mg/kg. Anesthesia was maintained by ciprofol 1 to 1.5mg/kg/h or propofol 3 to 5mg/kg/h. The primary outcome of the study was PONV after surgery 1h and 24h. Secondary outcomes included heart rate (HR), mean arterial blood pressure (MAP), SpO 2 before anesthesia (T1), 3 min after anesthesia (T2) and at the end of surgery (T3); the time of consciousness loss, recovery, hysteroscopy and discharge; and the incidence of adverse drug reactions such as hypotension, respiratory depression, bradycardia and injection pain was recorded in the two groups. Results: Compared with group P, MAP and SpO2 at T2 were significantly increased in group C ( P < 0.05). Although there was no significant difference in the incidence of PONV at 1h and 24h after surgery between 2 groups ( P > 0.05), the incidence of hypotension, injection pain and respiratory depression in group C were significantly reduced, compared with group P. ( P < 0.05). Conclusion: Compared with propofol, ciprofol has a similar incidence of PONV and lower adverse effects such as hypotension, injection pain and respiratory depression in outpatient hysteroscopy. Keywords: postoperative nausea and vomiting, ciprofol, propofol, hysteroscopy Hysteroscopy in outpatient clinics is considered the gold standard for evaluating intrauterine lesions, providing significant assistance in the early diagnosis and treatment of diseases. 1 The emergence of the concept of comfort care in medicine has led to the widespread adoption of painless hysteroscopy in outpatient settings. However, postoperative nausea and vomiting (PONV) is the most common adverse event after surgery. Studies have shown that the incidence of PONV is as high as 20–37%. 2 Despite the unclear PONV mechanism that drives the hindbrain central pattern generator (emesis) and forebrain pathways (nausea), several high-risk factors have been identified such as young age, female sex, lack of smoking, and a history of motion sickness. 3 Patients undergoing hysteroscopy in China are mostly young women with very low smoking rates, which is a high-risk group for PONV. Previous studies have shown that propofol, a first-line anesthetic and sedative medication, can effectively reduce PONV in gynecological surgeries. 4 However, it also has drawbacks such as injection pain and significant impact on respiratory and circulatory systems. 5 Ciprofol, a new intravenous sedative anesthetic, is an (R)-isomer small-molecule compound and a short-acting GABAA receptor agonist. It exerts its sedative and anesthetic effects by enhancing GABA-mediated chloride ion influx, offering advantages such as rapid onset, minimal circulatory suppression, and less injection pain, compared with propofol. 6,7 To the best of my knowledge, few studies reported on the effects of ciprofol on PONV after outpatient hysteroscopy. Therefore, our research aims to take PONV after surgery 1h and 24h as primary objectives and test the hypothesis that the incidence of PONV in ciprofol was lower than in propofol when patients undergoing outpatient hysteroscopy. The study included patients scheduled for outpatient hysteroscopy from September 2023, to May 2024. Eligible patients were aged between 18 and 75 years, had a BMI between 18 and 30 kg/m2, and were classified as ASA I or II. Exclusion criteria included a history of psychiatric or neurological disorders, recent upper respiratory tract infection, severe pulmonary, hepatic, or renal insufficiency, allergies to soy products or eggs, and a history of alcohol or drug abuse. Patients were randomly grouped to one of the two groups using a random number table: the ciprofol group (Group C) and the Propofol group (Group P). This study was approved by the ethical committee of The First Affiliated Hospital of t -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal